Global Interstitial Lung Disease Pipeline Surpasses 120+ Therapies: Major FDA Milestones and Clinical Progress Highlighted by DelveInsight

Global Interstitial Lung Disease Pipeline Surpasses 120+ Therapies: Major FDA Milestones and Clinical Progress Highlighted by DelveInsight
DelveInsight, a prominent life sciences market intelligence and consulting organization, has unveiled its newest report, "Interstitial Lung Disease Pipeline Insight, 2026" delivering a comprehensive analysis of the fast-evolving therapeutic environment for Interstitial Lung Disease (ILD). With over 120 companies advancing more than 120 therapeutic assets, the ILD pipeline is witnessing remarkable scientific innovation, clinical advancement, and regulatory acceleration.
The publication provides detailed insights into FDA approvals, active clinical studies, novel treatment candidates, mechanism-of-action (MoA) advancements, administration route patterns, and strategic initiatives anticipated to reshape ILD treatment paradigms in the coming years.

Request a complimentary sample report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Accelerating Global Innovation in Interstitial Lung Disease Therapies
Based on DelveInsight's comprehensive evaluation, the ILD pipeline demonstrates strong research and development engagement from leading biopharmaceutical players, including AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Boehringer Ingelheim, Prometheus Biosciences, Bayer, Insmed, Roche, Ark Biosciences, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, Taiho Pharmaceutical, Syndax Pharmaceuticals, Galecto Biotech, CSL Behring, AstraZeneca, among several emerging innovators.
These organizations are developing therapeutic solutions addressing fibrosis, inflammatory pathways, autoimmune mechanisms, immune system modulation, and tissue repair processes-reflecting the complex and multifactorial biology underlying ILD.

Access the Free Sample PDF to explore Interstitial Lung Disease Pipeline Therapeutic Assessment:
https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Therapies Poised to Redefine the ILD Market Landscape
A wide spectrum of innovative investigational treatments is progressing through different phases of clinical development. Noteworthy pipeline candidates include:
• AD-214
• Abatacept
• ATYR1923
• Inhaled Pirfenidone
• RO-0220912
• Lung stem cell-based therapies
• Bardoxolone methyl
• Pamrevlumab
• Deupirfenidone
• INOpulse
• OATD-01
• LT0011
• GDC-3280
• BI 1015550
• PRA023
• Yifenidone
• Riociguat
• Treprostinil Palmitil
• BMS 986278
• Zinpentraxin alfa
• LTI-03
• HZN-825
• ENV-101
• PLN-74809
• TAS-115
• Axatilimab
• GB0139
• CSL312
• Saracatinib
• And additional candidates
Spanning small molecules to advanced cell and gene therapy platforms, these investigational agents are expected to meaningfully reshape the ILD treatment ecosystem by introducing more precise, effective, and better-tolerated options.

Recent Clinical Milestones Shaping the ILD Treatment Paradigm
• December 2025: Boehringer Ingelheim's JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in adults.5 This represents a new treatment option in the U.S. for this debilitating lung condition, with JASCAYD being the first and only preferential phosphodiesterase 4B (PDE4B) inhibitor with immunomodulatory and antifibrotic effects approved in this indication.5 The FDA approval is based on results from the pivotal Phase III FIBRONEERTM-ILD clinical trial, the largest clinical trial program in PPF to date.5 Results showed that nerandomilast effectively slowed lung function decline in PPF with similar permanent discontinuation rates to placebo.
• February 2025: Boehringer Ingelheim reported positive Phase III data for nerandomilast, supporting its potential expansion into a second therapeutic indication. Results from the FIBRONEER-ILD Phase III study (NCT05321082) demonstrated improved lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). This follows earlier favorable outcomes in IPF that underpinned a New Drug Application (NDA) submission.
• March 2024: Boehringer Ingelheim initiated a randomized, double-blind, placebo-controlled trial assessing BI 1015550 in PF-ILD patients over a minimum duration of 52 weeks.
• April 2024: The company launched the INTENSE observational study to examine associations between lung function deterioration and symptom burden in connective tissue disease (CTD)-associated PF-ILD patients treated with Nintedanib.
• January 2024: aTyr Pharma commenced a proof-of-concept study evaluating Efzofitimod in systemic sclerosis-associated ILD (SSc-ILD).
These ongoing trials and forthcoming data readouts are anticipated to significantly influence future treatment strategies, regulatory outcomes, and capital allocation within the ILD domain.

Further product-specific insights are available in the full report. Download the ILD pipeline study to explore emerging therapies in detail: https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease: A Multifaceted and Progressive Disorder
Interstitial Lung Disease encompasses a diverse group of pulmonary conditions marked by inflammation and progressive scarring (fibrosis) of lung tissue, ultimately impairing oxygen transfer. Patients frequently experience persistent shortness of breath, chronic cough, and fatigue, with symptoms progressively worsening and adversely affecting quality of life.
Potential causes include:
• Environmental exposures (e.g., asbestos, silica)
• Autoimmune disorders (e.g., rheumatoid arthritis, scleroderma)
• Drug-induced toxicity
• Genetic susceptibility
Diagnosis typically involves clinical evaluation, high-resolution computed tomography (HRCT), pulmonary function assessments, and, in selected cases, lung biopsy. Treatment strategies aim to reduce inflammation, slow fibrotic progression, extend survival, and improve overall patient functioning.
As advances in biomarker discovery, pathway-specific targeting, and inhaled delivery technologies continue to emerge, the outlook for ILD management is becoming increasingly optimistic.

Administration Routes and Molecule Type Trends in the ILD Pipeline
DelveInsight's report classifies pipeline therapies according to Route of Administration (RoA):
• Oral
• Intravenous
• Subcutaneous
It further segments candidates by molecule category, including:
• Small molecules
• Peptides
• Polymers
• Cell therapies
• Gene therapies
This therapeutic diversity underscores the industry's commitment to enhancing drug delivery efficiency, patient adherence, and clinical outcomes.

Comprehensive Assessment of the Interstitial Lung Disease Pipeline
The ILD development landscape spans the entire clinical continuum:
• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and Discovery stages
• Discontinued and inactive programs

Each therapeutic candidate is evaluated across multiple dimensions, including:
• Mechanism of action
• Target biology
• Clinical performance
• Regulatory milestones
• Strategic collaborations
• Molecular structure and format
• Administration route
The report also examines partnership models, licensing agreements, mergers and acquisitions, funding trends, and academic collaborations fueling innovation within the ILD space.

Download the Sample PDF to gain detailed insights into ILD drugs and emerging therapies:
https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease Market Outlook: Growth Catalysts, Challenges, and Unaddressed Needs
The global ILD market is expected to experience significant expansion driven by several key factors.
Market Growth Drivers
• Increasing global incidence of fibrosing ILDs
• Broader adoption of antifibrotic treatment regimens
• Progress in inhaled, targeted, and precision-based therapies
• Sustained investment in research and development

Market Challenges
• Delays in accurate diagnosis and disease heterogeneity
• Elevated costs of antifibrotic agents and biologics
• Limited long-term efficacy data for newer therapies
• Variability in therapeutic response among patients

Unmet Clinical Needs
• Tools enabling earlier and more precise diagnosis
• Clearly validated biomarkers
• Safer long-term treatment options with improved tolerability
• Subtype-specific targeted interventions

For in-depth analysis of ILD therapeutics, clinical progress, and emerging innovations:
Download the Sample PDF - Interstitial Lung Disease Pipeline Analysis - https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading business consulting and market research organization dedicated exclusively to the life sciences industry. The firm delivers comprehensive, end-to-end solutions designed to equip pharmaceutical and biotechnology companies with actionable intelligence, strategic guidance, and data-driven decision-making support. By combining extensive domain expertise with advanced analytical capabilities, DelveInsight enables organizations to accelerate growth, enhance operational performance, and strengthen competitive positioning across the global healthcare landscape.

This release was published on openPR.